REGULATORY STRATEGY & MARKET ACCESS FOR MEDICAL DEVICES AND IVDS
Clear Pathway. Protected Access. Regulatory Strategy Built to Get You to Market and Keep You There.
No sales pitch - leave with prioritised next steps for your route to market
1,000+Regulatory submissions across the UK and EU
over 20
Notified Bodies & Approved Bodies Reviewed SciMed-supported documentation
11+ years
Supporting MedTech & IVD Clients Across the Full Device Lifecycle
Make the right regulatory decisions before you commit budget, and protect your ability to keep selling as requirements, evidence expectations and market rules change. SciMed helps MedTech and IVD manufacturers define defensible regulatory pathways, pressure-test evidence strategy, and maintain market continuity across UK, EU and US requirements.
Why Regulatory Strategy Cannot be Treated as ‘Just’ Paperwork
The most expensive regulatory problems often start early:
A claim written too broadly,
A classification assumption that goes unchallenged,
A predicate strategy that proves weak,
A legacy-device change that threatens transition status,
A Notified Body question that exposes a gap that should have been found months earlier.
By then, the cost is not just regulatory effort. It is delayed launch, repeated testing, avoidable documentation rework, lost management confidence and, in the worst cases, interrupted legal sellability.
Market access is not a single approval milestone. For medical device and IVD manufacturers, it is the ability to launch, sell, change and maintain products compliantly across shifting UK, EU and US requirements.
Who Are These Services For?
These services are designed for:
Manufacturers preparing for UK, EU or US market entry
Teams unsure about classification, intended purpose, claims or conformity assessment route selection
Companies managing MDR, IVDR, UKCA, MHRA or EUDAMED transition risks
Manufacturers facing Notified Body feedback, audit findings or CAPA pressure
Overstretched RA/QA teams that need senior regulatory judgement and execution support
Founders and leadership teams who need a defensible plan before committing major budget
Need a clearer view of how your device will be classified and regulated?
We’ll flag the highest-priority classification and conformity questions, and outline what a full feasibility pathway looks like.
SciMed’s Regulatory Strategy & Market Access services
-
The Right Route, Confirmed Before You Build the Wrong Evidence Package
Our Regulatory Pathway & Classification Strategies are structured assessments of how your device or IVD should be qualified, classified and routed to market; conducted before your team commits to an evidence generation programme.
SciMed reviews your intended purpose, applicable classification rules under MDR Annex VIII, IVDR Annex VIII or UK/FDA frameworks, predicate or equivalence logic, and the regulatory route options available to you across the markets you are targeting.
The output is a documented, senior-reviewed position your team can act on, not a preliminary opinion that unravels when a Notified Body or regulatory authority asks the next question.
-
Claims That Hold Up to Regulatory Scrutiny Without Undermining Your Commercial Position
An Intended Purpose, Claims & Borderline Product Review is a structured analysis of how your product is described, positioned and regulated, and whether those three things are actually aligned.
SciMed reviews your intended purpose statement, labelling claims, promotional language and any borderline or combination product questions against MDR, IVDR, UKCA and applicable FDA definitions. Misaligned claims are one of the most common sources of Notified Body questions, evidence scope creep and unexpected reclassification.
This review identifies those risks early and produces a revised intended purpose and claims framework your regulatory, clinical and marketing teams can work from.
-
A Sequenced, Evidence-Aware Launch Plan Your Leadership Can Commit to with Confidence
UK, EU & US Market Entry Strategy is a comparative assessment of the regulatory routes, evidence expectations, timeline dependencies and market placement obligations relevant to each jurisdiction you are targeting.
SciMed maps your classification, conformity assessment route, clinical or performance evidence requirements and post-market obligations across CE marking under MDR/IVDR, UKCA under UK MDR 2002, and 510(k), De Novo or PMA pathways under FDA.
Where sequencing decisions affect budget and timeline. Whether CE marking data can support a 510(k), or whether UKCA can be achieved via a transitional route.
SciMed identifies the options and their trade-offs so leadership can make an informed commercial decision before committing to the evidence programme.
-
On-the-market Status Protected Through Every Phase of Regulatory Transition
MDR, IVDR, UKCA & MHRA Transition Support is a managed programme of regulatory activity designed to maintain market access through changing transition deadlines, registration obligations and lifecycle requirements.
SciMed assesses your current transition status across EU MDR and IVDR sell-off provisions, UK Responsible Person and UKCA obligations, and MHRA registration requirements, and identifies the actions, timelines and documentation needed to remain compliant.
For manufacturers carrying legacy CE-marked devices or IVDs into a transitional period, or managing multiple product lines with different transition dates, this service provides the structured oversight needed to avoid an interruption to legal sellability.
-
Registration Completed Correctly, So Market Placement Is Not Held Up by Avoidable Admin
EUDAMED & MHRA Registration Support covers the planning and execution of device, economic operator and UDI registration obligations under EU MDR/IVDR and UK MDR 2002.
SciMed reviews your registration scope, confirms your economic operator structure and responsibilities, supports EUDAMED actor and device registration, and manages MHRA device registration requirements including UK Responsible Person appointment where needed.
Registration errors and omissions, particularly around UDI assignment, GMDN codes and economic operator roles, are a common source of delay at the point of market placement. This service ensures the administrative foundations are in place before they become a problem.
-
Know Whether Your Change Triggers a New Submission Before You Commit to It
A Change Control Regulatory Impact Assessment is a structured review of whether a proposed change to your device, IVD, software, manufacturing process, supplier or claims constitutes a significant change requiring Notified Body involvement, a new conformity assessment or a regulatory submission.
SciMed assesses the change against the significant change criteria under EU MDR Article 54, IVDR Article 49, UK MDR 2002 and applicable FDA guidance, and produces a documented rationale supporting your change control decision.
For manufacturers managing multiple changes across a product lifecycle, this service provides the regulatory judgement and written justification your quality system requires, and that a Notified Body or competent authority will expect to see if challenged.
-
Reviewer-Ready Documentation and a Response Strategy That Moves the File Forward
Notified Body Readiness & Response Strategy covers two related challenges: preparing your technical documentation and quality system for Notified Body review before submission, and managing the response process when questions, requests for information or major findings arrive during assessment.
SciMed reviews your documentation against the applicable Notified Body's known scrutiny approach, identifies gaps likely to generate questions, and supports structured, evidence-backed responses that address reviewer concerns directly rather than generating further rounds of clarification.
For manufacturers already in a review cycle, SciMed helps triage findings, prioritise responses and rebuild the file where the original approach has been challenged.
-
A Structured Path Back to Compliance When Findings Put Your Market Access at Risk
Audit, CAPA & Remediation Strategy is a senior-led response service for manufacturers facing Notified Body audit findings, major nonconformities, competent authority inspection outcomes or internal audit failures that threaten regulatory standing or market access.
SciMed reviews the findings, assesses root cause, and helps build a CAPA plan that is both technically credible and structured to satisfy the expectations of the issuing authority. Where findings relate to technical documentation, clinical evidence or post-market surveillance, SciMed provides the regulatory and scientific expertise needed to close gaps that a quality team alone cannot resolve.
The goal is a documented, defensible response that restores compliance and protects the ability to keep selling.
-
A Clear View of Whether Your Evidence Supports the Market Access Decisions Ahead — Not Just the Regulatory Ones
An Evidence-to-Access Gap Audit is a structured review of your clinical, performance, post-market surveillance and PMCF evidence against both the regulatory standards required for conformity and the practical expectations of the markets, payers and procurement bodies you are targeting.
SciMed assesses whether your CER, PMCF plan, SSCP, performance evaluation report or equivalent documentation is sufficient to withstand Notified Body scrutiny, and whether it supports the commercial access strategy your business is planning.
Where gaps exist, SciMed produces a prioritised remediation plan that addresses the most material risks to both regulatory approval and market placement.
Tell us your device type, target markets, and where your team is currently stuck. We'll confirm which services apply and what a realistic plan looks like.
What Should You Pressure-Test Before Committing Budget?
Before investing heavily in testing, technical documentation or submission preparation, your team should confirm:
Intended purpose and claims,
Device or IVD qualification,
Classification and applicable rules,
UK, EU and US route options,
Predicate or equivalence logic,
Clinical or performance evidence sufficiency,
PMS, PMCF, PSUR or post-market evidence needs,
Registration and market placement dependencies, and
Change-control risks that could affect access later.
SciMed turns that uncertainty into a decision-ready plan your technical, regulatory and leadership teams can act on.
SciMed’s services are for you if…
You're likely a good fit for SciMed's Regulatory Strategy & Market Access Services if you recognise yourself here:
You're preparing to enter a new market…
and need confidence that you've chosen the right regulatory pathway before committing significant time and budget.
You're facing classification or pathway uncertainty...
...and need a defensible strategy for intended purpose, classification, claims, evidence requirements, and route selection.
You're concerned about maintaining market access...
...and want to ensure MDR, IVDR, MHRA, UKCA, EUDAMED, registration, or transition requirements don't disrupt your ability to keep selling.
Your regulatory team is stretched thin...
...and needs experienced strategic support to make complex decisions without adding headcount.
You've received difficult Notified Body feedback...
...and need an organised, evidence-backed response strategy to regain momentum and reduce uncertainty.
You're planning a significant product change...
...and need to understand whether it could trigger a new submission, conformity assessment, or regulatory action.
You're a MedTech founder or senior leader...
...and need clear regulatory direction before investing in testing, evidence generation, technical documentation, or market expansion activities.
You value scientific rigour and practical advice...
...and want clear recommendations, honest assessments, and decision-ready outputs rather than generic consultancy reports.
You want a long-term regulatory partner...
...not just someone who helps you reach the next milestone before disappearing.
If you're looking for someone to simply validate an existing plan or guarantee a favourable regulatory outcome, we're probably not the right fit. Our clients value honest advice, rigorous scientific assessment, and commercially practical strategies that stand up to scrutiny.
Why SciMed for Regulatory Strategy & Market Access?
Regulatory strategy is not about producing another roadmap.
It's about making the right decisions before you commit significant time, money, and internal resources.
A weak classification rationale, an unclear intended purpose, a flawed evidence strategy, or an avoidable market access obstacle can create months of delay and substantial rework.
SciMed helps you make defensible decisions early, protect market access over time, and navigate regulatory uncertainty with confidence. We combine scientific rigour, regulatory expertise, and commercial awareness to create strategies that are practical, evidence-based, and built for long-term success.
SciMed deliver Excellence Beyond Deliverables
Our Approach:
We help you decide before you spend.
Before you invest in testing, technical documentation, submissions, or market expansion, we pressure-test the pathway, evidence requirements, and regulatory assumptions that could create expensive delays later.
We focus on market access continuity.
Regulatory approval is only part of the challenge. We help you maintain your ability to sell, update, and expand your products compliantly through changing regulations, registrations, transitions, and post-market obligations.
We explain the “why,” not just the “what.”
You'll receive clear recommendations supported by regulatory rationale, allowing leadership teams, investors, and regulatory stakeholders to make informed decisions with confidence.
We act as your extended regulatory team.
Whether you're a start-up building capability or an established manufacturer with limited internal capacity, we integrate seamlessly with your team and provide senior-level expertise when you need it most.
We prioritise scientific integrity.
We tell you what you need to hear, not what you want to hear. If we identify risks, evidence gaps, or weaknesses in a proposed pathway, we'll explain them clearly and help you build a realistic route forward.
Wecreate reviewer-ready and baordroom-ready outputs.
Our work is designed to withstand regulatory scrutiny while also providing leadership teams with the clarity they need to make strategic business decisions.
Our mission is to provide regulatory support that combines rigorous science, flawless execution, and professional client service. When you work with SciMed, you gain more than regulatory advice, you gain a long-term partner committed to helping you reach and maintain market access with confidence.
Proof: Regulatory Strategy & Market Access Case Studies
See how SciMed have helped manufacturers establish defensible classification rationales, respond to Notified Body questions, and maintain market access across the UK & EU markets..
Ready to make the right decision before you spend?
Book a Regulatory Discovery Call
Tell us your device type, target markets, and where you're facing regulatory uncertainty. We'll give you an honest read on the decisions you need to get right before committing budget, time, or resources to a submission, an evidence programme, or a new market.